Journal of Clinical Oncology, Vol 6, 276-281, Copyright © 1988 by American Society of Clinical Oncology

ARTICLES

Chemotherapy for breast cancer decreases plasma protein C and protein S

JS Rogers 2d, AJ Murgo, JA Fontana and PC Raich
Department of Medicine, West Virginia University Medical Center, Morgantown 26506.

An increased incidence of thromboembolic events has been described in women receiving chemotherapy for breast cancer. The etiology of this enhanced thrombotic state has not been defined. We performed serial coagulation studies in 15 women during 1 monthly cycle of cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy for breast cancer; seven adjuvant and eight metastatic. Plasma protein C levels were measured by anticoagulant, amidolytic, and antigenic techniques. Antigen levels of both total and free plasma protein S were quantitated by immunoelectrophoresis. Plasma levels of protein C, an important vitamin K-dependent inhibitor of blood coagulation and a profibrinolytic agent, and protein S, a cofactor for protein C, decreased 1 and 2 weeks after initiation of chemotherapy compared with pretreatment values. Plasma levels of factor VII and fibrinogen also decreased. The changes in protein C and protein S may contribute to the enhanced thrombotic tendency described in this setting. Possible mechanisms for the decreases in plasma protein C, protein S, factor VII, and fibrinogen are discussed.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Sousou and A. A. Khorana New Insights Into Cancer-Associated Thrombosis Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 316 - 320. [Abstract] [Full Text] [PDF]

				E. N. Brown and J. D. Herrington Review of the Relationship Between Venous Thromboembolism, Malignancy and Its Treatment Journal of Pharmacy Practice, April 1, 2008; 21(2): 126 - 137. [Abstract] [PDF]

				A. A. Khorana, H. A. Liebman, R. H. White, T. Wun, and G. H. Lyman The Risk of Venous Thromboembolism in Patients with Cancer ASCO Educational Book, January 1, 2008; 2008(1): 240 - 248. [Abstract] [Full Text] [PDF]

				C. W. Francis, A. K. Kakkar, M. N. Levine, and G. H. Lyman Prevention of Venous Thromboembolism in Patients with Cancer ASCO Educational Book, January 1, 2008; 2008(1): 250 - 256. [Abstract] [Full Text] [PDF]

				Y. Ramot and A. Nyska Drug-Induced Thrombosis--Experimental, Clinical, and Mechanistic Considerations Toxicol Pathol, February 1, 2007; 35(2): 208 - 225. [Abstract] [Full Text] [PDF]

				M. Adess, R. Eisner, S. Nand, J. Godwin, H. L. Messmore Jr, and W. H. Wehrmacher Thromboembolism in Cancer Patients: Pathogenesis and Treatment Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 254 - 266. [Abstract] [PDF]

				B. Demirkan, M. A. Ozcan, A. Alacacioglu, F. Yuksel, B. Undar, and M. Alakavuklar The Effect of Anthracycline-Based (Epirubicin) Adjuvant Chemotherapy on Plasma TAFI and PAI-1 Levels in Operable Breast Cancer Clinical and Applied Thrombosis/Hemostasis, January 1, 2006; 12(1): 9 - 14. [Abstract] [PDF]

				S. F. Ely Potential Risk of a Common Hereditary Thrombophilia and Adjuvant Chemotherapy for Low-Stage Breast Cancer J. Clin. Oncol., June 20, 2005; 23(18): 4242 - 4243. [Full Text] [PDF]

				M. P. Davis Hematology in palliative medicine American Journal of Hospice and Palliative Medicine, November 1, 2004; 21(6): 445 - 454. [Abstract] [PDF]

				M. W. Saif, S. F. Leitman, G. Cusack, M. Horne, A. Freifeld, D. Venzon, A. PremKumar, K. H. Cowan, R. E. Gress, J. Zujewski, et al. Thromboembolism following removal of femoral venous apheresis catheters in patients with breast cancer Ann. Onc., September 1, 2004; 15(9): 1366 - 1372. [Abstract] [Full Text] [PDF]

				M. Isildak, G. S. Guven, and S. Emri Mesothelioma and venous thrombosis Can. Med. Assoc. J., July 6, 2004; 171(1): 11 - 11. [Full Text] [PDF]

				H.-M. M. B. Otten, J. Mathijssen, H. ten Cate, M. Soesan, M. Inghels, D. J. Richel, and M. H. Prins Symptomatic Venous Thromboembolism in Cancer Patients Treated With Chemotherapy: An Underestimated Phenomenon Arch Intern Med, January 26, 2004; 164(2): 190 - 194. [Abstract] [Full Text] [PDF]

				N. Goldenberg, S. R. Kahn, and S. Solymoss Markers of Coagulation and Angiogenesis in Cancer-Associated Venous Thromboembolism J. Clin. Oncol., November 15, 2003; 21(22): 4194 - 4199. [Abstract] [Full Text] [PDF]

				G.-F. von Tempelhoff, K. Pollow, D. Schneider, and L. Heilmann State-of-the-Art Review : Chemotherapy and Thrombosis in Gynecologic Malignancy Clinical and Applied Thrombosis/Hemostasis, April 1, 1999; 5(2): 92 - 104. [PDF]

				M. Fanucchi, J. Glaspy, J. Crawford, J. Garst, R. Figlin, W. Sheridan, D. Menchaca, D. Tomita, H. Ozer, and L. Harker Effects of Polyethylene Glycol-Conjugated Recombinant Human Megakaryocyte Growth and Development Factor on Platelet Counts after Chemotherapy for Lung Cancer N. Engl. J. Med., February 6, 1997; 336(6): 404 - 409. [Abstract] [Full Text] [PDF]

				S. J. Jubelirer Venous Thromboembolism and Malignant Brain Tumors: A Review Clinical and Applied Thrombosis/Hemostasis, April 1, 1996; 2(2): 130 - 136. [Abstract] [PDF]

				M. C. Donaldson and A. D. Whittemore Thromboembolism From Occult Subclavian Arterial Stenosis During Chemotherapy for Breast Carcinoma Arch Surg, February 1, 1995; 130(2): 224 - 226. [Abstract] [PDF]